RU2018101152A - Использование биогенеза микрорнк в экзосомах для диагностики и лечения - Google Patents

Использование биогенеза микрорнк в экзосомах для диагностики и лечения Download PDF

Info

Publication number
RU2018101152A
RU2018101152A RU2018101152A RU2018101152A RU2018101152A RU 2018101152 A RU2018101152 A RU 2018101152A RU 2018101152 A RU2018101152 A RU 2018101152A RU 2018101152 A RU2018101152 A RU 2018101152A RU 2018101152 A RU2018101152 A RU 2018101152A
Authority
RU
Russia
Prior art keywords
cancer
subject
therapy
level
mirnas
Prior art date
Application number
RU2018101152A
Other languages
English (en)
Other versions
RU2018101152A3 (ru
Inventor
Рагу КЭЛЛАРИ
Сонья МИЛОУ
Original Assignee
Борд оф Риджентс, Дзе Юниверсити оф Тексас Систем
Бэс Израиль Деаконесс Медикал Центр, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Борд оф Риджентс, Дзе Юниверсити оф Тексас Систем, Бэс Израиль Деаконесс Медикал Центр, Инк. filed Critical Борд оф Риджентс, Дзе Юниверсити оф Тексас Систем
Publication of RU2018101152A3 publication Critical patent/RU2018101152A3/ru
Publication of RU2018101152A publication Critical patent/RU2018101152A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Theoretical Computer Science (AREA)
  • Plant Pathology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Claims (10)

1. Способ лечения субъекта, включающий:
(a) получение уровня: (i) одной или нескольких микроРНК, выбранных из микроРНК, представленных в табл. 5; (ii) уровня предшественника микроРНК; (iii) RISC-белка или (iv) активности процессинга микроРНК во фракции экзосом образца, полученного от субъекта;
(b) выбор субъекта, обладающего раковым биомаркером, на основании уровня одной или нескольких микроРНК, предшественника микроРНК, RISC-белка или активности процессинга микроРНК; и
(c) лечение выбранного субъекта с помощью противораковой терапии.
2. Способ по п. 1, отличающийся тем, что противораковая терапия представляет собой химиотерапию, радиационную терапию, гормональную терапию, таргетную терапию, иммунотерапию или хирургическое лечение.
3. Способ по п. 2, отличающийся тем, что субъекта предварительно лечили от ракового заболевания.
4. Способ по п. 3, отличающийся тем, что у субъекта предварительно хирургическим путем удалили опухоль.
5. Способ по п. 1, отличающийся тем, что раковое заболевание представляет собой рак молочной железы, рак легких, рак головы и шеи, рак простаты, рак пищевода, рак трахеи, рак головного мозга, рак печени, рак мочевого пузыря, рак желудка, рак поджелудочной железы, рак яичников, рак матки, рак шейки матки, рак яичек, рак толстого кишечника, рак прямой кишки или рак кожи.
6. Способ по п. 5, отличающийся тем, что раковое заболевание представляет собой рак молочной железы.
7. Способ по п. 2, отличающийся тем, что противораковая терапия нацелена на головной мозг.
RU2018101152A 2013-03-15 2014-03-14 Использование биогенеза микрорнк в экзосомах для диагностики и лечения RU2018101152A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791301P 2013-03-15 2013-03-15
US61/791,301 2013-03-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015144212A Division RU2644247C2 (ru) 2013-03-15 2014-03-14 Использование биогенеза микрорнк в экзосомах для диагностики и лечения

Publications (2)

Publication Number Publication Date
RU2018101152A3 RU2018101152A3 (ru) 2019-02-21
RU2018101152A true RU2018101152A (ru) 2019-02-21

Family

ID=51581257

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018101152A RU2018101152A (ru) 2013-03-15 2014-03-14 Использование биогенеза микрорнк в экзосомах для диагностики и лечения
RU2015144212A RU2644247C2 (ru) 2013-03-15 2014-03-14 Использование биогенеза микрорнк в экзосомах для диагностики и лечения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015144212A RU2644247C2 (ru) 2013-03-15 2014-03-14 Использование биогенеза микрорнк в экзосомах для диагностики и лечения

Country Status (15)

Country Link
US (2) US20160024503A1 (ru)
EP (2) EP3527670B1 (ru)
JP (2) JP6554458B2 (ru)
KR (1) KR102183406B1 (ru)
CN (2) CN109852695B (ru)
AU (2) AU2014239309B2 (ru)
BR (1) BR112015023275B1 (ru)
CA (2) CA2905081C (ru)
ES (1) ES2966571T3 (ru)
HK (1) HK1218143A1 (ru)
IL (2) IL241409B (ru)
MX (2) MX2015013141A (ru)
PT (1) PT3527670T (ru)
RU (2) RU2018101152A (ru)
WO (1) WO2014152622A1 (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016150475A1 (en) * 2015-03-22 2016-09-29 Universite De Liege Circulating micrornas for the diagnosis of breast cancer
CN104774966B (zh) * 2015-05-01 2017-07-28 北京博奥医学检验所有限公司 肺腺癌miRNA标记物
EP3307890A1 (en) 2015-06-10 2018-04-18 Board of Regents, The University of Texas System Use of exosomes for the treatment of disease
CN107151661A (zh) * 2016-03-02 2017-09-12 上海润腾生物科技有限公司 一种人外泌体蛋白、试剂盒及其应用
CN106202984B (zh) * 2016-08-26 2018-09-04 赵毅 一种基于多层复杂网络对肿瘤miRNA标志物的筛选方法
WO2018071806A1 (en) * 2016-10-13 2018-04-19 University Of Louisville Research Foundation, Inc. Exosomal biomarkers for diagnosis and prognosis of cancer and related methods
CN110024037B (zh) 2016-11-30 2023-06-27 微软技术许可有限责任公司 经由连接的dna随机存取存储系统
US10793897B2 (en) * 2017-02-08 2020-10-06 Microsoft Technology Licensing, Llc Primer and payload design for retrieval of stored polynucleotides
WO2019104445A1 (en) * 2017-11-30 2019-06-06 Provincial Health Services Authority Methods for evaluating head and neck cancers
CN112236131A (zh) 2018-03-29 2021-01-15 技术研究及发展基金有限公司 包含pten抑制剂的囊泡及其用途
WO2019201277A1 (en) * 2018-04-17 2019-10-24 Wang Mong Lien Method for blocking stress-induced tumor progression
EP3786307A4 (en) 2018-04-25 2022-08-24 Toray Industries, Inc. KIT, DEVICE AND METHOD FOR DETECTION OF BLADDER CANCER
EP3869177A4 (en) 2018-10-17 2022-08-10 H.U. Group Research Institute G.K. PROCEDURE FOR RECOVERING EXTRACELLULAR VESICLES
US11766484B2 (en) 2019-01-03 2023-09-26 International Business Machines Corporation Exosome vessels for delivery of molecular cargo
US20220136011A1 (en) 2019-02-08 2022-05-05 Board Of Regents, The University Of Texas System Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction
WO2020163553A1 (en) * 2019-02-08 2020-08-13 Virginia Commonwealth University Mda-7/il-24 for cancer treatment and methods of monitoring same
KR102424454B1 (ko) * 2019-02-26 2022-07-22 서울대학교산학협력단 Tut4/7 발현 조절인자를 포함하는 암 예방 또는 치료용 약학적 조성물
JP2022538834A (ja) * 2019-07-02 2022-09-06 オハイオ・ステイト・イノベーション・ファウンデーション 皮膚脳相関を利用する神経変性疾患療法
US20220275455A1 (en) * 2019-07-08 2022-09-01 Preferred Networks, Inc. Data processing and classification for determining a likelihood score for breast disease
CN110358835A (zh) * 2019-07-26 2019-10-22 泗水县人民医院 生物标志物在胃癌检测、诊断中的应用
KR102212699B1 (ko) * 2019-08-12 2021-02-05 한국원자력의학원 유방암 예방 또는 치료용 조성물
CN110607361A (zh) * 2019-10-08 2019-12-24 南京市儿童医院 miR-431作为靶点在制备促进SP表达的药物中的应用
CN114902043A (zh) 2019-12-23 2022-08-12 富士瑞必欧株式会社 细胞外囊泡的回收方法和采血管
EP3862442A3 (en) * 2020-02-04 2021-10-27 Artemisia S.p.A. Method for the early diagnosis of cancer by means of ddpcr analysis of mirna in liquid biopsy
EP3862441A3 (en) * 2020-02-04 2021-10-27 Artemisia S.p.A. Method for the early diagnosis of cancer by means of ddpcr analysis of mirna and protein markers in liquid biopsy
KR102318328B1 (ko) * 2020-04-13 2021-10-27 고려대학교 산학협력단 Gcc2 단백질을 과발현하는 엑소좀 기반 암 진단 또는 예후 예측용 마커 조성물
CN115461445A (zh) 2020-04-15 2022-12-09 合同会社予幸集团中央研究所 细胞外囊泡的回收方法
CN111920961B (zh) * 2020-08-14 2023-09-08 福建医科大学附属协和医院 一种治疗癌症的药物
WO2022054976A1 (ko) * 2020-09-08 2022-03-17 (주)유로테크 전립선암 진단 점수 계산 방법 및 그 용도
KR102497196B1 (ko) 2020-09-08 2023-02-07 (주)유로테크 전립선암 진단 점수 계산 방법 및 그 용도
WO2022102246A1 (ja) * 2020-11-11 2022-05-19 国立研究開発法人物質・材料研究機構 細胞で産生された膜小胞に由来する塩基配列を解析する方法、その装置、及び、そのプログラム
CN112662752B (zh) * 2021-01-18 2022-08-23 中国农业大学 一种诊断用生物标志物的应用
CN112760381B (zh) * 2021-02-08 2022-11-01 复旦大学附属中山医院 一种检测肺腺癌预后的miRNA试剂盒
KR102310302B1 (ko) * 2021-02-08 2021-10-06 을지대학교 산학협력단 엑소좀 기반 방광암 진단을 위한 정보 제공 방법
CN116121377A (zh) * 2022-11-01 2023-05-16 山西医科大学 一种食管鳞癌外泌体富含的miRNA作为诊断食管鳞癌的标志物中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030064949A1 (en) 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
KR100519384B1 (ko) 2002-08-13 2005-10-06 (주)누백스 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도
CN1281279C (zh) * 2004-09-16 2006-10-25 浙江大学 针对表皮生长因子基因的小干扰核糖核酸分子及其用途
WO2009015357A1 (en) * 2007-07-25 2009-01-29 University Of Louisville Research Foundation, Inc. Exosome-associated microrna as a diagnostic marker
CN104975089A (zh) * 2007-09-14 2015-10-14 俄亥俄州立大学研究基金会 人外周血微泡中的mirna表达和其用途
CN101827613A (zh) * 2007-09-27 2010-09-08 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
ES2703363T3 (es) 2008-02-01 2019-03-08 Massachusetts Gen Hospital Uso de microvesículas en el diagnóstico y pronóstico de tumores cerebrales
ES2600165T3 (es) * 2008-02-28 2017-02-07 The Ohio State University Research Foundation Antagonistas de miR-32 para aumentar la respuesta del cáncer de próstata a la apoptosis
US20110172295A1 (en) * 2008-04-11 2011-07-14 The University Of North Carolina At Chapel Hill METHODS AND COMPOSITIONS FOR THE REGULATION OF microRNA PROCESSING
EP2294196A1 (en) * 2008-06-06 2011-03-16 Centre National de la Recherche Scientifique - CNRS Use of endo-lysosomal system and secreted vesicles (exosome-like) in treatments and diagnostics based on small rna and experimental study of small rna
EP3181705A1 (en) * 2008-11-12 2017-06-21 Caris Life Sciences Switzerland Holdings GmbH Methods and systems of using exosomes for determining phenotypes
US9469876B2 (en) * 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
US10081542B2 (en) * 2010-04-20 2018-09-25 University of Florida Research Foundation, lnc. Nanozymes, methods of making nanozymes, and methods of using nanozymes
ES2629502T3 (es) * 2011-03-11 2017-08-10 Children's Medical Center Corporation Métodos y composiciones relacionados con exosomas de células madre mesenquimales
AU2012245188A1 (en) * 2011-04-20 2013-12-05 Smith, Larry J Methods and compositions for modulating gene expression using components that self assemble in cells and produce RNAi activity
AU2012294458A1 (en) 2011-08-08 2014-02-27 Caris Life Sciences Switzerland Holdings Gmbh Biomarker compositions and methods
US9777042B2 (en) 2011-12-15 2017-10-03 Morehouse School Of Medicine Method of purifying HIV/SIV Nef from exosomal fusion proteins
DK3076949T3 (da) 2013-12-04 2019-11-25 Univ Texas Fremgangsmåde til isolering af kræftcelle-afledte eksosomer
KR102493872B1 (ko) * 2016-09-02 2023-01-30 다이서나 파마수이티컬, 인크. 4'-포스페이트 유사체 및 이를 포함하는 올리고뉴클레오타이드

Also Published As

Publication number Publication date
CA3209023A1 (en) 2014-09-25
US20200255831A1 (en) 2020-08-13
US11926824B2 (en) 2024-03-12
EP2971162A1 (en) 2016-01-20
CN105264092A (zh) 2016-01-20
AU2014239309B2 (en) 2020-03-05
EP2971162A4 (en) 2016-11-16
EP3527670B1 (en) 2023-10-18
BR112015023275A2 (pt) 2017-07-18
JP2018138057A (ja) 2018-09-06
CN109852695A (zh) 2019-06-07
MX2020005165A (es) 2020-08-20
KR20160006673A (ko) 2016-01-19
RU2018101152A3 (ru) 2019-02-21
CN109852695B (zh) 2023-11-21
KR102183406B1 (ko) 2020-12-11
CA2905081A1 (en) 2014-09-25
HK1218143A1 (zh) 2017-02-03
IL241409B (en) 2020-04-30
JP2016520803A (ja) 2016-07-14
AU2014239309A1 (en) 2015-10-08
AU2020203590A1 (en) 2020-06-18
ES2966571T3 (es) 2024-04-23
RU2015144212A (ru) 2017-04-21
BR112015023275A8 (pt) 2018-01-23
IL273829B (en) 2021-12-01
US20160024503A1 (en) 2016-01-28
EP2971162B1 (en) 2019-05-08
MX2015013141A (es) 2016-06-21
BR112015023275B1 (pt) 2022-06-21
JP6554458B2 (ja) 2019-07-31
CN105264092B (zh) 2019-02-22
IL273829A (en) 2020-05-31
CA2905081C (en) 2023-10-03
IL241409A0 (en) 2015-11-30
EP3527670A1 (en) 2019-08-21
JP6807351B2 (ja) 2021-01-06
WO2014152622A1 (en) 2014-09-25
RU2644247C2 (ru) 2018-02-08
PT3527670T (pt) 2024-01-18
AU2020203590B2 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
RU2018101152A (ru) Использование биогенеза микрорнк в экзосомах для диагностики и лечения
IL280707A (en) Diagnostic and therapeutic methods for treating breast cancer
PH12019501959A1 (en) Therapeutic rna
IL281256A (en) Combined treatment for the treatment of triple-negative breast cancer
WO2017053889A3 (en) Flt3 directed car cells for immunotherapy
IL263678B (en) Compounds for use in the treatment of breast cancer +ar
IL253947A0 (en) Methods of treating breast cancer with taxane therapy
MX364705B (es) Sistemas y metodos para tratar el cancer y/o aumentar la funcion de organos.
EA201790404A1 (ru) Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака
WO2016036994A8 (en) Method of analysis allowing avoidance of surgery
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
EA201590694A1 (ru) Ly75 как мишень для терапии и диагностики злокачественных опухолей
PT3458610T (pt) Tratamento terapêutico de cancro da mama baseado no estado de c-maf
HK1245152A1 (zh) 減少腦癌幹細胞的生長、遷移和侵入以及改善腦腫瘤患者存活率的方法和組合物
MA40458A (fr) Méthodes de traitement du cancer du col de l'utérus
HK1245133A1 (zh) 用伊立替康脂質體治療乳腺癌
IL284850A (en) Methods of treating breast cancer with toctinib
WO2016059241A3 (en) Lung cancer diagnostics and therapeutics with mir-660
MX2018005867A (es) Integracion de las caracteristicas tumorales con el indice de cancer de mama.
ZA201200998B (en) Anti-angiogenesis therapy for the treatment of previously treated breast cancer
EA201792294A1 (ru) Комбинированное лечение (варианты) с применением серибантумаба
SG11202012203PA (en) In vivo controlled combination therapy for treatment of cancer
SG11202013190YA (en) Combination therapy with targeted tgf-b inhibition for treatment of advanced non-small cell lung cancer
EA202091143A1 (ru) Способы лечения и поддерживающей терапии рака мочевого пузыря с использованием гемцитабина
UA78354U (ru) Способ лечения базально-клеточного рака кожи

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190902